Drug Trial Radar · NCT02103283
A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Oct 2014
Primary completion
Aug 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Apr 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.
Conditions
- Diabetic Macular Edema
Interventions
TeprotumumabDrug
Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of RV001in subjects with Diabetic Macular EdemaTime frame: Change from Baseline to Week 9
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
David S Boyer
Beverly Hills, California
David A Eichenbaum, MD
St. Petersburg, Florida
Diana Do, MD
Omaha, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.